i would like to know if anyone has tried to add a small dose (1-3mg range) of free-base Harmine/Harmaline to e-liquid in an atomizer, to note the effects they may have as MAO inhibitors. i cite those specifically, because they are easily/cheaply extractable/available, and like many others, i think they may be the key missing elements. i myself find that i do not miss Nicotine when i am vaping, but i do not achieve the state after 10 hits or so where i say to myself "i am done, i had enough", ie, the quick point where i can put down the vaporizer like a finished cigarette, and move on to other things. i also wonder if there may be dual actions to the Harmala alkaloids:
1. potentiating the effect of Nicotine, so that less does more, for a longer time interval.
2. anihilating the desire for further psychoactive effects.
#1 seems to be something people are aware of, but #2 crosses my mind from studies such as these:
EXAMPLE 2 A second experiment was conducted using a 10 mg/kg dose of harmaline administered interperitoneally on a daily basis for five days. Similar results were observed. The treated group showed ethanol consumption ranging from one half to one quarter that of control group during the five days of daily harmaline administration. The five day post treatment period showed the harmaline group drinking fifty to twenty five percent less ethanol than the control group. Additional research showed harmine to produce similar physiological effects as harmaline at approximately 400 percent the dose of harmaline. EXAMPLE 3 A twenty-three year old, 140 pound male human subject using one to three grams of ....... daily via nasal administration was provided a single dose of 500 mg of harmaline HCl per os. Subject immediately discontinued ....... use. Subject's ....... use was interrupted for a period of four months. Subject had been previously treated with 500 mg of a total alkaloid extract of T. iboga with no significant effect on drug use. Conversely, it should be noted, however, that three persons successfully treated with ibogaine had no response to the administration of harmaline in interrupting their drug use. EXAMPLE 4 A thirty-two year old, 136 pound male human subject using twenty dollars worth of ...... a day (approximately 40 mg/day) via IV route. The subject interspersed his use of ...... with 15 mg and 30 mg injections of morphine and unknown quantities of pantopon. The subject was given an IV injection of 100 mg of harmaline HCl. A second 100 mg IV injection of harmaline HCl was given six hours later. Subject discontinued ...... use for a period of three weeks after which contact with the subject was lost. Subject's cigarette consumption which had been between one and two packs a day immediately ceased. This continued for ten days after which subject began smoking at a reduced rate. It should be noted that IV administrations of harmala alkaloids are significantly more toxic than oral administrations and it is advised that they not be used in medical practice. EXAMPLE 5 Male subject, twenty-four years of age, weighing 153 pounds was using 20 mg of ...... and 250 mg of ....... per day both via IV route and was drinking twelve to sixteen cups of coffee per day. Subject was administered 750 mg of harmaline base in a split dose of 500 mg followed by 250 mg twenty minutes later. Subject's use of ...... and ....... ceased immediately. Coffee consumption initially dropped to one half to one cup per day but, was increased to three to four cups per day within two weeks. ....... use ceased for a period of two months at which time subject began nasal use of approximately 50 mg/day. Within three months subject was using ....... and amphetamine IV and barbiturates per os. Subject had not returned to ...... use at this time but, contact with the subject was lost and no further information was available. EXAMPLE 6 Male subject, age twenty-two, estimated weight 120 pounds, using two grams of amphetamine and/or desoxyephedrine per day via IV route was administered 500 mg of harmaline base. Subject immediately ceased stimulant use. Contact was lost two weeks later when subject left city in which treatment was administered for location unknown. The present invention, thus, affords an effective means of treating a chemical dependency disorder, an abuse syndrome or a combination thereof. The effectiveness thereof is evidenced by either a reduced or interrupted intake of substances tending to cause the disorder or syndrome. Thus, as described hereinabove, the treatment of the present invention leads to either a reduced or interrupted intake of such substances by the subject mammal. Further, this result may be obtained without generating a subsequent chemical dependency disorder or abuse syndrome based upon the treatment.
